SCHEMBL3931349

SCHEMBL3931349

COc1ccc(-c2cc3ncnc(N(CC4=COCO4)Cc4ccccc4)c3s2)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 5/20 0.47
CSF1R P07333 1/20 0.37
EGFR P00533 5/20 0.35
RIPK2 O43353 1/20 0.34
NOS1 P29475 1/20 0.33
KIT P10721 2/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAP3K8 P41279 1/20 0.32
ACHE P22303 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071094 0.90 STK17B (0.43) STK17BCSF1REGFRKITMAP3K8
SCHEMBL3933109 0.90 STK17B (0.35) STK17BCSF1REGFRKITMAP3K8
SCHEMBL4068341 0.89 STK17B (0.40) STK17BEGFRKIT
SCHEMBL3928357 0.88 EGFR (0.44) STK17BEGFRNOS1NPC1RAB9A
SCHEMBL4067150 0.88 RAB9A (0.45) STK17BCSF1REGFRNOS1KIT
SCHEMBL4064310 0.88 IKBKB (0.34) STK17BCSF1REGFRKITMAP3K8
SCHEMBL3927058 0.87 STK17B (0.40) STK17BEGFRKITALDH1A1
SCHEMBL4068418 0.87 KIT (0.43) STK17BEGFRKITNPC1RAB9A
SCHEMBL3927276 0.86 STK17B (0.37) STK17BEGFRNOS1TUBB4ATUBB
SCHEMBL3930210 0.86 HSD17B2 (0.41) STK17BCSF1REGFRKITNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 STK17B 1911/4885CSF1R 1260/4885EGFR 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.